ANA Investigates American Neurological Association

Glioblastoma is the most common malignant brain tumor and one of the most aggressive solid tumors. Much progress has been made in the understanding and classification of gliomas, but progress in terms of prolonging survival has been limited. Several recent investigational therapies are bringing new hope. Our guest today is Dr. Eric Wong from Brown University. He is an international expert on advanced treatments for glioblastoma and a Professor of Medicine, Radiation Oncology, Neurosurgery, and Neurology at Brown University. He was interviewed by Dr. Christoph Stretz, a Vascular and Critical Care neurologist at Brown. Series 5, Episode 6
Featuring:
Guest: Dr. Eric Wong, Brown University Interviewer: Dr. Christoph Stretz, Brown University

Brain death is one of the most controversial and ethically complex topics in neurology, but it's a regular part of our clinical practice. Late last year, a new set of guidelines was published that address some of the thorniest technical and ethical issues in the clinical determination of brain death. For this discussion, we are joined by Dr. Ariane Lewis, a professor in the departments of Neurology and Neurosurgery, as well as the director of the Division of Neurocritical Care at NYU Langone Medical Center, and Dr. Matthew Kirschen, an assistant professor of Anesthesiology and Critical Care at the hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia. They were interviewed by Dr. Masoom Desai of the University of New Mexico. Series 5, Episode 5
Featuring:
Guests: Dr. Ariane Lewis & Dr. Matthew Kirschen Interviewer: Dr. Masoom Desai Disclosures: None

Small fiber neuropathy is one of those conditions in neurology that can feel frustratingly intangible. Even for patients with severe neuropathic pain and autonomic symptoms, in about half of cases, the usual lab testing doesn't reveal a cause. There's increasing evidence that autoimmunity may be a factor in some of these cases of idiopathic small fiber neuropathy, but how to test and who to treat with immunosuppression is less clear. Our guest today, Anne Louise Oaklander, is an Associate Professor of Neurology at Massachusetts General Hospital and an Assistant in Neuropathology. She's known for her work on small fiber neuropathies and in this episode we'll talk about new autoantibodies associated with small fiber neuropathy and where we are in treating this challenging condition. Series 5, Episode 4
Featuring:
Guest: Dr. Anne Louise Oaklander Interviewer: Dr. Adeline Goss Disclosures: None

The recent FDA approval of lecanemab, an amyloid-sequestering agent, has been hailed as a breakthrough in the treatment of Alzheimer disease. Critics of the drug have pointed to its cost, risks, and treatment burden. Now that lecanemab is being administered in clinics across the country - how is it changing the lives of people with Alzheimers and their families? Dr. Megan Richie, neurohospitalist at UCSF, spoke to Dr. Seth A. Gale, Co-Director of the Brain Health Program and Assistant Professor of Neurology at Harvard Medical School. Dr. Gale has been involved in creating the clinical program that is delivering lecanemab to patients at Brigham and Women’s Hospital and Massachusetts General Hospital, with the first patients receiving the drug this month. Series 5, Episode 3
Featuring:
Guest: Seth A. Gale, MD - Co-Director of the Brain Health Program, and Assistant Professor of Neurology at Harvard Medical School Interviewer: Megan Richie, MD - Neurohospitalist at UCSF and Chair of the ANA Education Innovation Committee Disclosures: Dr. Gale disclosed that he is a site Principal Investigator or Sub-Investigator (at Brigham and Women's Hospital) for several clinical trials in Alzheimer disease. Sponsors for those studies include Biogen, Eisai, Roche, Genentech, and Eli Lilly. I am on a scientific advisory board for MindAhead DE, with the opportunity for honoraria.

Chronic pain can be incredibly challenging -- for patients, of course, and also for their physicians. On this episode of ANA investigates, Dr. Adeline Goss talks to Dr. Prasad Shirvalkar of UCSF about a new possible strategy for treating chronic pain: deep brain stimulation. Series 5, Episode 2
Featuring:
Guest: Dr. Prasad Shirvalkar of UCSF Interviewer: Dr. Adeline Goss Disclosures: Dr. Shirvalkar disclosed that Medtronic Inc, donated devices for research, but no direct financial support

The brain and its vasculature used to be considered separate domains. But in the last decade, we’ve learned more about the interplay between brain cells and vascular cells. Pathological studies are revealing a surprising degree of overlap between cerebrovascular disease and neurodegenerative disease. All of this has led to the coining of a new word: the neurovasculome. Our guest today is Dr. Eric Smith, an author of a recent scientific statement about the neurovasculome in the journal Stroke. Dr. Smith is a Professor of Neurology, Radiology, and Community Health Sciences at the University of Calgary, and the holder of the endowed Katthy Taylor Chair in Vascular Dementia. He was interviewed about the neurovasculome by Dr. Christoph Stretz, a Vascular and Critical Care neurologist at the Warren Alpert Medical School of Brown University. Series 5, Episode 1
Featuring:
Guest: Eric Edward Smith, MD, MPH, FRCPC, FAHA, University of Calgary Interviewer: Christoph Stretz, MD, Brown University Disclosures: Dr. Smith disclosed that he receives personal consulting fees from Alnylam Pharmaceuticals and Eli Lilly